BridgeBio Pharma BBIO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 95.1%-0.7pp | 95.8%0.0pp | 95.8%-0.4pp | 96.2%+0.8pp | 95.4%-2.9pp | |
| Operating margin | -90.5%+13.7pp | -104.2%+68.1pp | -172.4%+106pp | -278.4%+269pp | -547.6%-280pp | |
| Net margin | -125.9%+20.1pp | -146%+81.8pp | -227.7%+105pp | -332.9%+198pp | -531.2%-286pp | |
| EBITDA margin | -89.6%+13.6pp | -103.2%+67.7pp | -170.9%+105pp | -276%+267pp | -543%-279pp | |
| Free cash flow margin | -76.8%+12.3pp | -89%+76.6pp | -165.6%+113pp | -278.4%— | —— | |
| Returns | ||||||
| Return on assets | -64.8%+14.2pp | -79%+17.9pp | -96.9%-13.1pp | -83.8%-5.6pp | -78.2%-4.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×+0.1× | 0.4×+0.2× | 0.3×+0.1× | 0.1×-0.2× | |
| Inventory turnover | 1.5×— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 1.5×-1.2× | 2.8×-1.1× | 3.9×-1.3× | 5.2×+0.6× | 4.6×-0.1× | |
| Quick ratio | 1.5×-1.2× | 2.7×-1.1× | 3.8×-1.3× | 5.1×+0.5× | 4.5×-0.1× | |
| Cash ratio | 1.1×+0.5× | 0.6×-2.4× | 3×-1.3× | 4.3×+0.7× | 3.6×-0.9× | |
| Leverage | ||||||
| Debt-to-assets | 2.4×+2.4× | 0×-2.0× | 2.1×+2.1× | 0×0.0× | 0×-0.5× | |
| Interest coverage | -7.1×-0.5× | -6.6×+0.2× | -6.9×-0.3× | -6.5×+1.6× | -8.1×-1.6× | |
| Per Share | ||||||
| Book value per share | -$11.70-7.4% | -$10.89-8.1% | -$10.08-7.4% | -$9.38-8.2% | -$8.67-9.9% | |
| Valuation | ||||||
| Market capitalization | $14.4B-2.3% | $14.74B+48.5% | $9.93B+17.6% | $8.44B+28.4% | $6.57B+26.8% | |
| Enterprise value | $16.77B+15.1% | $14.58B+28.6% | $11.34B+47.3% | $7.7B+27.4% | $6.04B+22.1% | |
| Price / sales | 24.8×-4.5× | 29.4×+1.3× | 28.1×-7.7× | 35.8×-15.8× | 51.6×+28.2× | |
| EV / sales | 28.9×-0.1× | 29×-3.0× | 32.1×-0.6× | 32.7×-14.8× | 47.4×+25.1× | |
| Free cash flow yield | -3.1%-0.1pp | -3%+2.9pp | -5.9%+1.9pp | -7.8%— | —— | |
| Earnings yield | -5.1%-0.1pp | -5%+3.1pp | -8.1%+1.2pp | -9.3%+1.0pp | -10.3%+0.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BridgeBio Pharma's profit margins?
- BridgeBio Pharma (BBIO) runs a 95.1% gross margin and a -90.5% operating margin, with a -125.9% net margin.
- Where do BridgeBio Pharma's ratios come from?
- Every ratio is computed from BridgeBio Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
